Furthermore, a strong association of the cancer risk with plasma ofCS-CD44 was observed not only in all-stage (Fig. 4n), but also in the early-stage patients, with increasing risk by plasma ofCS-CD44 decile, and the OR of malignant cancer for those in the top of CS-CD44 decile was 27.3 (95% CI = 14.7–50.6; P = 7.26 × 10−26, Fig. 4o). This evidence concerns the gene CD44 and cancer.